BACKGROUND Most prostate cancer‐related deaths occur in patients with castration‐
resistant prostate cancer (CRPC). Recent preclinical and clinical studies have identified …

Castrate-resistant prostate cancer represents a significant clinical challenge. Currently, the
standard treatment for patients with castrate-resistant prostate cancer is chemotherapy, after …

Nonmetastatic castration-resistant prostate cancer (nmCRPC)-defined as prostate-specific
antigen (PSA)> 2 ng/mL, testosterone castration levels< 1.7 nm/L, and the absence of …

We examined the comparative efficacies of first‐line abiraterone and enzalutamide in pre‐
and postdocetaxel settings in castration‐resistant prostate cancer (CRPC) through a trial …

The contemporary management of metastatic castration-resistant prostate cancer (mCRPC)
is evolving dramatically. Understanding the biology of this disease, positive phase III studies …

Most of the updates in the 2015 NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines) for Prostate Cancer center on the systemic therapy front, with a host of newer …

Prostate Cancer is the most commonly diagnosed malignancy and the second leading
cause of cancer-related death in men in the Western World. Docetaxel-based chemotherapy …

Background: Most patients receiving docetaxel-based chemotherapy for castration resistant
prostate cancer (CRPC) will eventually progress, and the optimal interventions for these …

What's known on the subject? and What does the study add? Castration resistance has
been appreciated for decades, and several mechanisms theorising on this effect have been …

Although aberrant androgen receptor (AR) signaling is a central mechanism for castration
resistant prostate cancer (CRPC) progression, AR‐independent growth signaling is also …